Aug. 1, 2025: Advocacy Update spotlight on pharmacy benefit managers under scrutiny

| 2 Min Read

Pharmacy Benefit Managers under scrutiny

The AMA is putting Pharmacy Benefit Managers (PBM) in the hot seat this week, as it released a new AMA analysis on PBMs and endorsed newly introduced legislation that would bring long-overdue transparency, accountability and fairness to the PBM industry.

Haven't subscribed?

Stay current on the latest on the issues impacting physicians, patients and the health care environment with the AMA’s Advocacy Update newsletter.

PBM markets are at risk of harming patients

A new AMA analysis demonstrates low competition in PBM markets across the nation and high vertical integration as the largest PBMs share ownership with health insurers. This analysis adds to growing concern over anticompetitive harm resulting from low competition and high vertical integration in the PBM industry. 

PBM stat: 9 out of the 10 largest PBMs share ownership with health insurers

Bipartisan legislation would rein in PBM abuses

The AMA formally endorsed (PDF) H.R. 4317, the “Pharmacy Benefit Manager (PBM) Reform Act of 2025,” introduced by Representatives Earl “Buddy” Carter (R-GA) and Debbie Dingell (D-MI). This bipartisan legislation seeks to bring long-overdue transparency, accountability and fairness to the PBM industry, an increasingly powerful force in the prescription drug supply chain. 

The PBM Reform Act would ban spread pricing in Medicaid, establish a transparent reimbursement model to ensure pharmacies are fairly compensated, decouple PBM compensation from drug prices, increase disclosure to employers and patients, and authorize the U.S. Department of Health and Human Services to enforce fair contract terms. 

Physicians have long raised concerns about the lack of clarity around formulary placement, utilization requirements such as step therapy, and patient cost-sharing obligations, all of which are heavily influenced by PBMs and often hidden from both prescribers and patients. A recent AMA analysis of competition in PBM markets (PDF) further highlights how vertical integration and market concentration threaten access and affordability.

The AMA commends Representatives Carter and Dingell for their leadership and remains committed to working with Congress to ensure prescription drugs are affordable, accessible and guided by medical expertise, not opaque corporate negotiations. H.R. 4317 was introduced on July 10 and currently has 21 cosponsors.

Your Powerful Ally

The AMA is your powerful ally, focused on addressing the issues important to you, so you can focus on what matters most—patients. We will meet this challenge together.

FEATURED STORIES

Open palm and health care icons

Want to turn your physician expertise into enterprise? Apply now

| 3 Min Read
Parent holds young child during doctor's appointment

New CMS model brings ACO approach to care for kids at high risk

| 5 Min Read
Heart shape plate with healthy salad surrounded by fruit and vegetables

Why nutrition education must become core training for physicians

| 4 Min Read
Team of doctors diagnose giant human blood vessel

What doctors wish patients knew about the deadly risk of stroke

| 15 Min Read